Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer

Gaetano Gallo 1,*; Giuseppina Vescio 1; Gilda De Paola 1; Giuseppe Sammarco 2

1 Department of Medical and Surgical Sciences, University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy; vescio@unicz.it (G.V.); gilda_depaola@libero.it (G.D.P.)
2 Department of Health Sciences, University of Catanzaro, Viale Europa, 88100 Catanzaro, Italy; sammarco@unicz.it
* Correspondence: gallog@unicz.it

Abstract: Colorectal cancer (CRC) is a genetically, anatomically, and transcriptionally heterogeneous disease. The prognosis for a CRC patient depends on the stage of the tumor at diagnosis and widely differs accordingly. The tumor microenvironment (TME) in CRC is an important factor affecting targeted cancer therapy. The TME has a dynamic composition including various cell types, such as cancer-associated fibroblasts, tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells, as well as extracellular factors that surround cancer cells and have functional and structural roles under physiological and pathological conditions. Moreover, the TME can limit the efficacy of therapeutic agents through high interstitial pressure, fibrosis, and the degradation of the therapeutic agents by enzymatic activity. For this reason, the TME is a fertile ground for the discovery of new drugs. The aim of this narrative review is to present current knowledge and future perspectives regarding the TME composition based on strategies for patients with CRC.

Keywords: tumor microenvironment; colorectal cancer; targeted therapy; angiogenesis; tumor-associated macrophages; regulatory T cells; cancer-associated fibroblasts

1. Introduction

Colorectal cancer (CRC) is among the three leading causes of cancer-related deaths, with an estimated one million new cases and 600,000 deaths per year globally [1]. The prognosis for a CRC patient depends on the stage of the tumor at diagnosis [2]. The current options for the standard treatment of CRC include surgical removal for stage I and most stage II CRCs and surgical removal and/or adjuvant radiochemotherapy (RCT) for high-risk stage II and stage III CRCs. For metastatic stage IV disease, the surgical removal of the primary CRC and/or metastatic lesions is not always indicated but may be followed by a variety of chemotherapeutic and targeted treatments.

The mortality rate widely differs by stage, being 8–13% for stage I/II, 11–47% for stage III, and almost 90% for stage IV [3]. The last, even after microscopically complete resection (R0), is associated with frequent disease recurrence within five years [4].

However, the recent advent of molecularly targeted therapies, such as cetuximab, panitumumab, and bevacizumab, which can be applied in combination with chemotherapy [5,6], has led to significant increases in progression-free survival (PFS) and overall survival (OS).

The tumor microenvironment (TME) has a dynamic composition, including various cell types, such as cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs), as well as extracellular factors that surround cancer cells (Figure 1) [7] and have functional and structural roles under physiological and pathological conditions.
Figure 1. Tumor microenvironment interactions. A macroscopic view of the molecular crosstalk between cancer-associated fibroblasts, endothelial vasculature, infiltrating immune cells, and malignant cells in the TME. Dynamic interactions governed by heterotypic signaling mechanisms between cell types modulate various stages of cancer progression (grey boxes). The role of exosomes in this cell-cell signaling is highlighted (blue and orange boxes). From Li et al. [7].

The TME can limit the efficacy of therapeutic agents through high interstitial pressure, fibrosis, and the degradation of the therapeutic agent by enzymatic activity. Therefore, it is a fertile ground for the discovery of new drugs (Figures 2 and 3) [8].
| **TRIAL** | **Drug combination** | **Patient population** | **Status** | **Phase** | **National Clinical Trial number** |
|-----------|---------------------|------------------------|------------|-----------|----------------------------------|
| **Anti-Angiogenics** | | | | | |
| Bevacizumab (Avastin) **SOLSTICE** | First-line TAS-102 + bevacizumab vs capectabine + bevacizumab | 854 untreated patients with MRC who were not candidates for inotocan or oxaliplatin therapy | Recruiting | 3 | NCT03869862 |
| **VITALITY** | First-line oxaliplatin, 5-fluorouracil, leucovorin + bevacizumab and vitamin C vs first-line oxaliplatin, 5-fluorouracil, leucovorin + bevacizumab | 428 previously untreated patients | Recruiting | 3 | NCT0296981 |
| Bevacizumab (Avastin) **Bevacizumab + binimetinib (MEK inhibitor) + pembrolizumab** | 40 patients with MRC without a response to prior therapy | Recruiting | 2 | NCT03475004 |
| Bevacizumab (Avastin) **Second-line bevacizumab + 5-fluorouracil, leucovorin + inotocan + onvansertib (an inhibitor of poto-line kinase 1)** | 44 patients with metastatic colorectal tumors with a mutation in KRAS for whom previous treatment failed or who are intolerant to oxaliplatin | Recruiting | 1/2 | NCT02829410 |
| **Afiblercept (Zaltrap)** | Afiblercept + pembrolizumab | 78 patients with advanced solid tumors | Recruiting | 1 | NCT02939959 |
| Ramucirumab (Cyramza) **RAMTAS** | TAS-102 + ramucirumab | 144 patients with advanced MRC that progressed on or after, or who did not tolerate, fluoropyrimidines, oxaliplatin, irinotecan, or anti-angiogenic therapy | Recruiting | 2b | NCT03553948 |
| **Donafenib (Mult-tyrosine kinase inhibitor)** | Second-line donafenib vs best supported care | 510 patients with MRC that progressed during or within 3 months of the final dose of therapy | Active, not recruiting | 3 | NCT02870582 |
| **Rogorelenib (Stivarga) **NEXT-REGIRI** | Salvage regorafenib + inotocan vs regorafenib only | 78 previously treated patients with MRC that progressed during or within 3 months of last treatment of standard therapy bearing genotype a/s of C0NN2 | Recruiting | 3 | NCT03829462 |
| **REMETY** | Second-line TAS-102 + regorafenib | 18 patients with MRC that progressed after standard therapy | Recruiting | 1 | NCT03039913 |
| **FOLFRINOX-R** | Regorafenib + 5-fluorouracil, leucovorin + inotocan + oxaliplatin (FOLFIRINOX) | 87 patients with metastatic colorectal tumors with mutant RAS | Recruiting | 1/2 | NCT03828799 |

**Figure 2.** Part I: Clinical Trials of Agents Designed to Target Tumor Stroma. From Fridman et al [9].

| **TRIAL** | **Drug combination** | **Patient population** | **Status** | **Phase** | **National Clinical Trial number** |
|-----------|---------------------|------------------------|------------|-----------|----------------------------------|
| **Regorafenib (Stivarga)** | Regorafenib + pembrolizumab | 75 patients with MRC who failed by or intolerant to oxaliplatin, irinotecan, or 5-fluorouracil | Not yet recruiting | 1/2 | NCT0657641 |
| **Checkpoint inhibitors** | | | | | |
| Atezolizumab (TECENTRIQ) | First-line FOLFOX 6 + bevacizumab + atezolizumab or atezolizumab alone or FOLFOX6 and bevacizumab | 347 patients with MSI tumors | Active, currently recruiting | 3 | NCT02997728 |
| **PEMBOLOZUMAB** | First line FOLFOX6 or FOLFIRI + bevacizumab or cetuximab + pembrolizumab | 308 patients with MSI tumors or a DNA mismatch repair-deficient tumors | Active, not recruiting | 3 | NCT02563002 |
| **Pembrolizumab (Keytruda)** | AXG-820 (anti-csf1 monocolonal antibody) + pembrolizumab | 116 patients with advanced solid tumors | Active, currently recruiting | 1b | NCT0713529 |
| **Pembrolizumab (Keytruda)** | Pembrolizumab + erlotinib (a histone diacetylase inhibitor) | 50 patients with DNA mismatch repair-proficient colorectal tumors who have not been treated with anti-PD1 or anti-PD-L1 | Active, not recruiting | 1b/2 | NCT0437136 |
| **Nivolumab (Opdivo) **CHECKMATE 6X8** | First-line FOLFOX + bevacizumab or nivolumab | 190 patients with MMS tumors or DNA mismatch repair-proficient tumors that cannot be treated by curative resection | Active and recruiting | 2/3 | NCT03414983 |
| **Nivolumab (Opdivo) ECHO024** | Epacadostat (indoleamine 2, 3-dioxygenase 1 inhibitor) + nivolumab + standard of care | 307 patients with advanced solid tumors including colorectal tumors | Active, not recruiting | 1/2 | NCT03270708 |
| **Duvamab (Elntra) STELLA001** | Duvamab + IPH-5401 (human monoclonal antibody against CSAR) | 100 patients with advanced solid tumors | Active and recruiting | 1 | NCT0365129 |
| **Duvamab (Elntra)** | Duvamab + OMNCS-102 (an adenovirus that encodes GMSF) | 78 patients with advanced peritoneal disease failed by chemotheraputry | Active and recruiting | 1/2 | NCT02938381 |
| **Other** | Third- or fourth-line nab-IRF or FOLFIRI vs best supportive care | 219 patients with MRC who failed by second- or third-line therapy | Active, not recruiting | 3 | NCT03559965 |
| **CCRT AND CCRS** | 384 patients with advanced colorectal or pancreatic tumors | 348 patients with advanced colorectal or pancreatic tumors | Active, not recruiting | 1/2 | NCT03186870 |

**Figure 3.** Part II: Clinical Trials of Agents Designed to Target Tumor Stroma. From Fridman et al [9].
It is a special niche in terms of acidity, hypoxia, and ischemia [10], and its components can modulate tumor progression by stimulating angiogenesis, suppressing apoptosis, or inducing immunodepression [11].

In 1971, Judah Folkman first described a revolutionary theory on the role of angiogenesis as a hallmark of cancer. In particular, the “angiogenic switch” is induced by hypoxic tumor cells that stimulate the overproduction of pro-angiogenic factors such as the vascular endothelial growth factor (VEGF) [12].

A better understanding of the TME is essential for the improvement and design of novel therapeutic strategies for colorectal cancer [13,14]. The aim of this narrative review is to present current knowledge regarding the composition of the TME and strategies for patients with CRC.

2. Definition

CRC is a genetically (mutation status, i.e., microsatellite instability (MSI)), anatomically, and transcriptionally (different molecular subtypes (CMSs)) heterogeneous disease [13,15].

Concerning the last, a molecular classification system based on six independent datasets for CRC gene expression has been developed for classifying both the tumor and the corresponding TME [16,17]. There are four different CMSs (Figure 4) [9].

![Figure 4. The consensus molecular subtypes. CMS1 and CMS4 tumors are highly infiltrated by immune cells, whereas CMS1 tumors are characterized by a Th1-cell response and activated and inflamed TME. These tumors can be treated with immune checkpoint inhibitors. CMS4 tumors have an inflamed, complement-rich, suppressive, and highly angiogenic TME that can be targeted with combination therapies. CMS2 tumors do not activate an antitumor immune response due to activation of the b-catenin pathway, and CMS3 tumors are considered to be metabolic tumors. CMS1 (14% of colorectal tumors); CMS2 (37% of colorectal tumors); CMS3 tumors (13% of colorectal tumors); CMS4 tumors (23% of colorectal tumors). From Fridman et al. [9].](image-url)

CMS1 and CMS4 are subtypes with large proportions of stromal tissue [18] and are associated with the lowest survival rates and worst prognoses for DFS and ODS. Interestingly, CAFs are widely present in the CMS4 subtype [17].
At the beginning of 2000, Hanahan and Weinberg described six essential alterations required in cell physiology to induce malignant growth in almost all tumors [19]. These characteristics can be found in the TME and are as follows: growth factor self-sufficiency, insensitivity to growth-inhibitory signals, the evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and the ability to invade and metastasize.

The idea of the TME or tumor stroma was first introduced at the end of the 19th Century by Paget [20] using the concept of a “seed” (cancer cells) and “soil” (the microenvironment). Paget suggested that the crosstalk between the TME and cancer cells should be closely studied to solve the problems of recurrence, metastasis, and drug resistance [21]. According to this theory, by evaluating preferential patterns of metastatic dissemination to certain organs, it can be observed that the TME provides support for tumor occurrence and progression. In fact, a combination of the colonizing cancer cells’ adaptability and a favorable environment is essential.

3. Angiogenesis and Hypoxia

Angiogenesis is a complex process with crucial roles in tumor growth and metastasis and is balanced by pro- and anti-angiogenic factors. Therefore, various steps of the angiogenic process have been targeted.

Regarding CRC, VEGF was discovered as a blood vessel regulator in the 1980s [22,23] and is one of the most studied protagonists of angiogenesis. In fact, bevacizumab, a monoclonal antibody against VEGF, was the first angiogenesis inhibitor approved for the treatment of renal cancer [24] and, subsequently, was used as a first-line option for metastatic CRC (mCRC) following the publication of data obtained by a combined analysis by Kabbinavar and colleagues [25]. They demonstrated, in three clinical trials, that patients with mCRC who were treated with fluorouracil/leucovorin alone or in combination with Bevacizumab showed an increase in mean OS, from 15.6 to 20.3 months, compared to controls.

The survival outcomes of patients with mCRC were further improved after the approval of the antibodies cetuximab and panitumumab, which target the epidermal growth factor receptor (EGFR) [26,27], a crucial element with a key role in the regulation of cell proliferation. In particular, the CRYSTAL trial demonstrated the efficacy of treating patients with wild-type KRAS with cetuximab in combination with folinic acid, 5-fluoruracil, and irinotecan (FOLFIRI) or leucovorin, 5-fluoruracil, and oxaliplatin (FOLFOX) in terms of OS. There was no statistically significant benefit of combination therapy for patients with a KRAS mutation, a well-known predictor of EGFR-therapy resistance [28].

A recent randomized phase III trial conducted in Germany, FIRE-3, demonstrated that FOLFIRI–cetuximab was slightly better than FOLFIRI–bevacizumab in mCRC patients regarding the overall response rate (72% vs. 56.1%; \(p = 0.0029\)) and OS (33.1 vs. 25.0 months; \(p = 0.0059\)) [29].

Ramucirumab and aflibercept have been approved, in combination with FOLFIRI, as second-line treatments [30,31]. Aflibercept is a recombinant fusion protein composed of the constant Fc domain of human IgG and the second and third immunoglobulin domains of VEGFR-1 and VEGFR-2, respectively. It acts as a ligand and inhibits the activity of VEGF-A and VEGF-B, rather than that of the placental growth factor (PIGF) [32]. Interestingly, no significant improvement in survival outcomes was demonstrated when aflibercept was used after bevacizumab [31]. Ramucirumab is a fully human monoclonal antibody (IgG1) that normally blocks the interaction between VEGF and its receptor and has already produced satisfactory results in treating lung and gastric cancers [33,34] but not mCRC.

Lastly, the angiopoietins (Ang-1; Ang-2; Ang-3; Ang-4) and their receptor Tie2 (TEK) deserve to be considered for the excellent results shown in preclinical models [35,36]. The search for new anti-angiogenic strategies continues, and trebananib and many others are under evaluation.

There is an important connection between angiogenesis and hypoxia. A hypoxic TME is characteristic of most locally advanced solid tumors and contributes to therapy
resistance [37,38]. Tumorigenesis is associated with high oxygen requirements that often cannot be satisfied by the surrounding cells, resulting in hypoxia. VEGF gene expression is stimulated by the latter, and the whole process is coordinated by the transcriptional factor hypoxia-induced factor-1 (HIF-1). Accordingly, topotecan, a topoisomerase 1 inhibitor, has been used for the treatment of solid tumors expressing HIF-1α [39,40]. Additionally, an antisense oligodeoxynucleotide targeting HIF-1α, EZN-2968, was recently developed [41] but still has a long way to go before becoming an approved therapy.

4. Cancer-Associated Fibroblasts

CAFs are the predominant non-malignant tumor cells in the TME and have an origin that is variable and not completely understood [42,43]. They may arise from epithelial cells, human bone marrow-derived mesenchymal cells, adipocytes, or hematopoietic stem cells in response to a stimulus mediated by EMT. Another source of CAFs is normal fibroblasts that undergo genetic alterations involving the inactivation of phosphatidylinositol-3, 4, 5-trisphosphate 3-phosphatase (PTEN) and p53 [44].

Fibroblasts can initially block the evolution of early-stage tumors [45]. However, they can later be modulated by tumor cells and stimulated to transform into CAFs. Transforming growth factor β (TGF-β) is the main chemotactic agent for fibroblasts that drives transdifferentiation into CAFs [46]. Moreover, TGF-β has a pro-tumorigenic effect on neutrophils and macrophages [47]. Unlike the other components of the TME, the transformation of fibroblasts is due to a chronic stimulus mediated by tumor cells, which can be defined as epigenetic [48] and is perfectly in line with the previously described two-step activation model (reversible–irreversible) [49].

Once they are activated, their presence in the TME is associated with poor clinical outcomes [45,50] due to the secretion of several molecules, such as stromal cell-derived factor 1 (SDF-1), which stimulates tumor angiogenesis [51] (through VEGFB, VEGFC, and PDGFC) and cancer cell colonization and metastasis [52].

Currently, therapy targeted at CAFs is mainly aimed at reducing oxidative stress, a mediator of the metabolic symbiosis between CAFs and tumor cells, and TGF-β [53–55]. Regarding the latter, several results have already been obtained [56,57].

5. Regulatory T Cells

Regulatory T cells (Tregs) are a subgroup of T-cells that, under physiological conditions, have several immunomodulatory effects on B and T cells, such as preserving the homeostasis of cytotoxic lymphocytes [58]. However, depending on the environmental stimuli received, Tregs can promote tumorigenesis. In particular, Tregs may suppress the immune response to autologous tumor cells, rendering immunotherapy ineffective [59,60]. A variety of targets for suppressing Tregs’ activity have recently been identified (Figure 5) [61].

The transcription factor forkhead box P3 (Foxp3) is one of the most specific Treg markers and, consequently, a target for new therapeutic strategies. Moreover, due to the expression of the cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), which interacts with B7, it has tumorigenetic activity (inhibits T-cells) [62].

Daclizumab is an FDA-approved monoclonal antibody raised against the CD25 receptor that has been proven to be effective for decreasing circulating T-regs, reducing the expression of both CD25 and Foxp3 [63], and increasing the release of IFN-γ.

Other than CTLA-4 and CD-25, further effort is currently aimed at blocking the activity of CD-28, one of the main stimuli for Treg activity [64].
Figure 5. Targeting strategies to eliminate or modulate Treg functions. Available antibodies, small molecules, or vaccines specific for different cell surface or intracellular targets. From Laplagne et al. [61].

6. Tumor-Associated Macrophages

TAMs are key immune cells that are present in high concentrations in the TME [65,66]. Once recruited by growth factors such as colony-stimulating factor-1 (CSF-1) and VEGF, inflammatory monocytes that have migrated into the TME differentiate into TAMs and produce immunosuppressive cytokines such as PGE2 and TGF-β for the suppression of T-cell proliferation [67].

They are highly plastic [68,69] and act as either anti- or pro-tumor agents depending on environmental stimuli, causing polarization into two phenotypes, classically activated macrophages (M1 cells) and alternatively activated macrophages (M2 cells) [65], which have roles in adaptive immunity corresponding to Th1 and Th2, respectively.

Their accumulation is often associated with a poor prognosis and enhanced metastasis in most solid cancers. In particular, a low M1/M2 ratio is related to a carcinogenic pattern [70], considering that M1 cells are usually activated by IFN-γ, which, along with Notch signaling and IFN-I, has an anti-tumor effect [70–72].

Conversely, M2 macrophages are involved in angiogenesis, tissue modeling and repair, and the differentiation of regulatory T-cells [73] and are driven by M-CSF, interleukin-3 (IL-3), IL-4, and IL-13 [74]. Furthermore, they participate in inflammation-associated carcinogenesis.

In a recent meta-analysis including 55 studies and 8692 patients, Zhang et al. [75] evaluated the infiltration of TAMs in patients with solid tumors using a pan-macrophage marker: CD68.
Interestingly, a high density of TAMs was associated with positive survival outcomes, only in patients with CRC. Nevertheless, colonic carcinoma may induce TAMs to promote angiogenesis and metastasis, contributing to the first step of cancerogenesis, that is, the epithelial-to-mesenchymal transition (EMT) [76,77].

Colon carcinoma cells are known to produce CSF-1 [76,78,79], which recruits macrophages to the tumor periphery, where they secrete promotility and angiogenic factors that facilitate tumor cell invasion and metastasis.

TAMs modulate the ECM. Matrix metalloproteinases, which are ECM-remodeling enzymes, regulate signaling pathways that control cell growth, inflammation, and angiogenesis. TAMs are a current target for immunotherapy. In fact, reprogramming towards an M1 phenotype could increase the effectiveness of chemotherapeutically targeted therapies (Figure 6) [80].

Figure 6. Targeting strategies to reprogram, eliminate, and inhibit TAM recruitment. Antibodies or molecules available to target surface, intracellular or soluble molecules involved in the phenotype, functions, and recruitment in the TME. From Laplagne et al. [61].
7. Myeloid-Derived Suppressor Cells

MDSCs represent a population of granulocytes and monocytes which, together with tumor-associated neutrophils (TANs), tumor-associated macrophages (TAMs), and regulatory dendritic cells, constitute the population of myeloid regulatory cells (MRC) [81–83]. This cell population expands rapidly as a result of infectious, inflammatory, and, especially, cancer processes, favoring its development and progression [83].

They were previously defined as “immature myeloid cells” or “myeloid suppressor cells” (MSC) [84,85], but, as these terms were too generic and misleading, they were replaced in 2007 with MDSCs, in order to better clarify the origin and function of these cells [86].

MDSCs can be divided into two groups: granulocytic or polymorphonuclear, phenotypically similar to neutrophils (PMN-MDSC) and monocytic MDSCs (M-MDSC) (Figure 7) [87,88].

![Figure 7](image-url)

**Figure 7.** Stages of myelopoiesis differentiation in cancer. Myelopoiesis is amplified during chronic inflammation to assist tumour progression and dissemination. The hematopoietic stem cells (HSC) differentiate into the common myeloid progenitor (CMP), which can further differentiate through the hematopoietic system. In physiological conditions, CMP can differentiate into neutrophils or into monocytes, and subsequently into dendritic cells (DC) or macrophages. However, with chronic inflammation, pro-inflammatory cytokines can skew the monocytic-myeloid-derived suppressor cells (M-MDSC) and tumour-associated macrophages (TAM), and granulopoiesis into polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) and tumour-associated neutrophils (TAN). From Law et al [87].
Furthermore, the existence of a third type of MDSC, called early-stage MDSCs, which have the ability to form colonies and other myeloid precursors, has been recently demonstrated [89].

The recruitment of MDSCs is mediated by various factors released during chronic inflammation such as chemokines [82,88,90,91], histamine [92,93] and prostaglandin E2 [94]. Among the chemokines, the C–C motif chemokine Ligand 2 (CCL2) plays a fundamental role in both determining the accumulation of MDSCs and increasing their immunosuppressive action with the consequent growth, progression, and development of metastases in patients with CRC [95].

Histamine can lead to the recruitment of Mo-MDSCs and PMN-MDSCs in different ways [92,93]. First, it promotes the expression of the enzyme arginase-1 (ARG1) and inducible NO synthase (iNOS) in Mo-MDSCs; second, it inhibits ARG1 and iNOS in PMNMDSCs by inducing the production of IL-13 and IL-14 [92,93]. The latter enzymes are fundamental in the correct metabolism of L-arginine and are involved in the proliferation of T lymphocytes, the expression of the CD3ζ chain, and the production of IFNγ [96–99].

Prostaglandin E2 (PGE2) is another crucial proinflammatory factor produced by COX-2 that determines the recruitment of MDSCs following STAT3 (Signal Transducer and Activator of Transcription 3) phosphorylation [100,101]. Consequently, persistent activation of the STAT3 pathway is associated with the growth of CRC cells [102,103]. Interestingly, the role of MDSCs was also observed in precancerous lesions [104].

Furthermore, MDSCs also play a role in determining high levels of MMP9 and pro-MMP9, which result in extracellular matrix degradation; they increase VEGF and, in the context of metastases, favor the transition process from epithelial to mesenchymal cells (EMT) [105–108].

There is, therefore, clear evidence of the involvement of MDSCs in the colorectal carcinogenesis process, and this could justify the use of these cells in the determination of prognosis and as therapeutic targets [83].

To date, there are several therapeutic approaches to combat the immunosuppressive action of MDSCs (Figure 8) [87]: (1) the first approach consists of reducing the number of MDSCs previously recruited into the neoplastic process through low-dose chemotherapy with 5-fluorouracil (5FU), paclitaxel, cisplatin or gemcitabine [109–112] and through tyrosine kinase inhibitors, such as Sunitinib [113,114]; (2) the second mechanism acts upstream, targeting the chemokine receptors involved in the recruitment of MDSCs [115–117]; (3) the third determines the down-regulation of ARG1 and iNOS, which act on the metabolism of L-Arginine [118,119]; (4) the fourth approach aims to promote the differentiation of MDSCs in mature myeloid cells with Tretinoin, also known as all-trans retinoic acid (ATRA) [120], in order to reduce their immunosuppressive effect.

However, targeting MDSCs in monotherapy, as well as using immunotherapy alone, can sometimes lead to insufficient outcomes in cancer treatment. For this reason, there are studies supporting the use of combination therapies [117,121,122].
Figure 8. Treatments used to target different mechanisms associated with pro-tumourigenic MDSC. There are multiple therapeutic approaches against MDSC to restore anti-tumour functions in immune cells and improve immunotherapy, in particular checkpoint inhibitors. These approaches include: (1) depleting MDSC populations through low-dose chemotherapy and tyrosine kinase inhibitors; (2) preventing MDSC recruitment to the TME by targeting chemokine receptors responsible for the recruitment and migration of MDSCs; (3) attenuating the immunosuppressive mechanisms of MDSC by downregulating the expression of ARG1 and iNOS, and reducing ROS generation; (4) inducing the differentiation of MDSC into mature myeloid cells to reduce MDSC population and remove their immunosuppression. From Law et al [87].

### 8. Emerging Treatments and Others

Immunotherapies using nanoparticles have recently drawn attention due to the possibility of both increasing drug delivery into solid tumors and avoiding the problem of drug resistance [123].

Organic and inorganic nanoparticles have been developed and can be used as carriers of antigens, proteins, or therapeutic agents, promoting specific and effective immune responses [124,125].
In fact, the delivery of chemo-agents may induce immunogenic cell death [126] in the TME and activate tumor-infiltrating antigen-presenting cells (APCs) [127]. Furthermore, nanoparticles can modulate a hypoxic TME by increasing oxygen release. Interestingly, Song et al. demonstrated the effectiveness of combined oxaliplatin-programmed death ligand-1 inhibition therapy in a colorectal cancer murine model [128]. Even though there are several delivery methods for nanoparticles, such as exosomes, chitosan, plasma membrane coating, and mesenchymal stem cells, there is still no standardization, especially regarding their efficacy and safety [123].

Two other important components of the TME are matrix metalloproteinases (MMPs) and mast cells.

MMPs are zinc-containing, calcium-dependent endopeptidases. They are responsible for the degradation of the extracellular matrix (ECM) and, consequently, tissue remodeling [129]. Their physiological expression is regulated by multiple hormones, growth factors, and cytokines, but their overexpression is involved in several disorders such as hemorrhoidal disease [130], inflammatory bowel disease [131], and cancer [132]. They are often expressed in advanced CRC and are associated with poor survival outcomes [133].

Mast cells are innate immune cells with a crucial role in the TME, and they represent the most studied components of the latter. A high mast cell density is correlated with increased vascularity, enhanced tumor growth, invasion, and poor clinical outcomes [134]. A low number of mast cells is associated with better survival in CRC [135]. Once activated, mast cells act as a trigger for the angiogenic switch, stimulating the production of VEGF, histamine, TNF-α, and several proteases [13]. The use of mast cell and MMP inhibitors [136] as adjuvant or neoadjuvant therapies in solid tumors [137] is currently under evaluation.

Our study has some limitations. This was a comprehensive narrative review that considered the main components of the TME. As a result, some elements that may play a role in the future, but are currently under development, may have been overlooked.

9. Conclusions

The tumor microenvironment is an important factor that affects targeted therapies for colorectal cancer. The downregulation of the pathways activated by the components most frequently present in the TME may improve the prognosis associated with the disease. However, future studies confirming this potential are needed.

Author Contributions: G.G.: Substantial contributions to the conception and design of the work; the acquisition, analysis, and interpretation of data for the work. Drafting the work and revising it critically for important intellectual content. Final approval of the version to be published. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy and integrity of any part of the work are appropriately investigated and resolved. G.V., G.D.P., and G.S. contributed equally to this work: acquisition, analysis, and interpretation of data for the work; Drafting the work and revising it critically for important intellectual content; Final approval of the version to be published. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Brenner, H.; Kloor, M.; Pox, C.P. Colorectal cancer. Lancet 2014, 383, 1490–1502. [CrossRef]
2. Gallo, G.; Sena, G.; Vescio, G.; Papandrea, M.; Sacco, R.; Trompetto, M.; Sammarco, G. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review. Ann. Ital. Chir. 2019, 90, 127–137. [PubMed]
3. O’Connell, J.B.; Maggard, M.A.; Ko, C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 2004, 96, 1420–1425. [CrossRef]

4. Fong, Y.; Fortner, J.; Sun, R.L.; Brennan, M.F.; Blumgart, L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann. Surg. 1999, 230, 309–318. [CrossRef]

5. Van Cutsem, E.; Cervantes, A.; Nordlinger, B.; Arnold, D.; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 3, III1–III9. [CrossRef]

6. Tarallo, S.; Ferrero, G.; Gallo, G.; Francavilla, A.; Clerico, G.; Realis Luc, A.; Manghi, P.; Thomas, A.M.; Vescio, G.; Segata, N.; et al. Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples. Msystems 2019, 4, e00289–e00319. [CrossRef]

7. Li, I.; Nabet, B.Y. Exosomes in the tumor microenvironment as mediators of cancer therapy resistance. Mol. Cancer 2019, 18, 32. [CrossRef] [PubMed]

8. Fang, H.; Declerck, Y.A. Targeting the tumor microenvironment: From understanding pathways to effective clinical trials. Cancer Res. 2013, 73, 4965–4977. [CrossRef]

9. Fridman, W.H.; Miller, I.; Sautes-Fridman, C.; Byrne, A.T. Therapeutic Targeting of the Colorectal Tumor Stroma. Gastroenterology 2020, 158, 303–321. [CrossRef]

10. Liotta, L.A.; Kohn, E.C. The microenvironment of the tumour-host interface. Nature 2001, 411, 375–379. [CrossRef] [PubMed]

11. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285, 1182–1186.

12. Sammarco, G.; Gallo, G.; Vescio, G.; Picciariello, A.; De Paola, G.; Trompetto, M.; Curro, G.; Ammundola, M. Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. J. Clin. Med. 2020, 9, 2852. [CrossRef] [PubMed]

13. Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic factor that promotes accumulation of ascites fluid. Science 1993, 260, 1306–1309. [CrossRef] [PubMed]

14. Lee, G.H.; Malietzis, G.; Askari, A.; Bernardo, D.; Al-Hassi, H.O.; Clark, S.K. Is right-sided colon cancer different to left-sided colorectal cancer?—A systematic review. Eur. J. Surg. Oncol. 2015, 41, 300–308. [CrossRef] [PubMed]

15. Leuk, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306–1309. [CrossRef] [PubMed]

16. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983–985. [CrossRef]

17. Yang, J.C.; Haworth, L.; Sherry, R.M.; Hwu, P.; Schwartzentruber, D.J.; Topalian, S.L.; Steinberg, S.M.; Chen, H.X.; Rosenberg, S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349, 427–434. [CrossRef]

18. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [CrossRef]

19. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 2019, 8, 98–101.

20. Trédan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2000, 99, 1441–1454. [CrossRef]

21. Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306–1309. [CrossRef] [PubMed]

22. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983–985. [CrossRef]

23. Yang, J.C.; Haworth, L.; Sherry, R.M.; Hwu, P.; Schwartzentruber, D.J.; Topalian, S.L.; Steinberg, S.M.; Chen, H.X.; Rosenberg, S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349, 427–434. [CrossRef]

24. Kabbavinar, F.F.; Hambleton, J.; Mass, R.D.; Hurwitz, H.I.; Bergsland, E.; Sarkar, S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 2005, 23, 3706–3712. [CrossRef] [PubMed]

25. Van Cutsem, E.; Kohne, C.H.; Hitre, E.; Zaluski, J.; Chang Chien, C.R.; Makhson, A.; D’Haens, G.; Pinter, T.; Lim, R.; Bodoky, G.; et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360, 1408–1417. [CrossRef] [PubMed]

26. Bouillart, J.Y.; Oliner, K.S.; Siena, S.; Tabernero, J.; Burkes, R.; Barigel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013, 369, 1023–1034. [CrossRef] [PubMed]

27. Khambara-Ford, S.; Garrett, C.R.; Meropol, N.J.; Basik, M.; Harbison, C.T.; Wu, S.; Wong, T.W.; Huang, X.; Takimoto, C.H.; Godwin, A.; et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007, 25, 3230–3237. [CrossRef]
48. Maintenance of melanoma T cell memory is dependent on IL-15. *Nat. Med.* 2004, 10, 1347–1354. [CrossRef] [PubMed]

49. Power, M.; Tschachler, E. HDAC inhibitors activate autophagy and induce apoptosis in prostate cancer cells. *J. Biol. Chem.* 2014, 289, 17826–17838. [CrossRef] [PubMed]

50. Ferguson, A.L.; Lee, Y.; Roffey, S.E.; Elson, E.L.; Granger, D.W. Humanized mice as a model for investigating immune responses in colorectal cancer. *Clin. Cancer Res.* 2005, 11, 3750–3757. [CrossRef] [PubMed]

51. Orimo, A.; Weinberg, R.A. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. *Cell Cycle* 2006, 5, 1597–1601. [CrossRef] [PubMed]

52. Kalluri, R. The biology and function of fibroblasts in cancer. *Nat. Rev. Cancer* 2016, 16, 582–598. [CrossRef] [PubMed]

53. Neuzillet, C.; Tijeras-Raballand, A.; Cohen, R.; Cros, J.; Faivre, S.; Raymond, E.; de Gramont, A. Targeting the TGFβ pathway for cancer therapy. *Pharmacol. Ther.* 2015, 147, 22–31. [CrossRef] [PubMed]

54. Smith, A.L.; Robin, T.P.; Ford, H.L. Molecular pathways: Targeting the TGF-β pathway for cancer therapy. *Clin. Cancer Res.* 2012, 18, 4514–4521. [CrossRef] [PubMed]

55. Akhurst, R.J.; Hata, A. Targeting the TGFbeta signalling pathway in disease. *Nat. Rev. Drug Discov.* 2012, 11, 790–811. [CrossRef] [PubMed]

56. Gorelik, L.; Flavell, R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. *Nat. Med.* 2001, 7, 1118–122. [CrossRef] [PubMed]

57. Calon, A.; Lonardo, E.; Berenguer-Llergo, A.; Espinet, E.; Hernandez-Mombliena, X.; Iglesias, M.; Sevillaño, M.; Palomo-Ponce, S.; Tauroiello, D.V.; Byrom, D.; et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. *Nat. Genet.* 2015, 47, 320–329. [CrossRef] [PubMed]

58. Gasteiger, G.; Hemmers, S.; Firth, M.A.; Le Floch, A.; Huse, M.; Sun, J.C.; Rudensky, A.Y. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. *J. Exp. Med.* 2013, 210, 1167–1178. [CrossRef] [PubMed]

59. Grossman, W.J.; Verbsky, J.W.; Barchet, W.; Colonna, M.; Atkinson, J.P.; Ley, T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity* 2004, 21, 589–601. [CrossRef] [PubMed]

60. von Boehmer, H. Mechanisms of suppression by suppressor T cells. *Nat. Immunol.* 2015, 16, 338–344. [CrossRef] [PubMed]

61. Laplagne, C.; Domagala, M.; Le Naour, A.; Quemerais, C.; Hamel, D.; Fournié, J.J.; Couderc, B.; Bousquet, C.; Ferrand, A.; Poupet, M. Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression. *Int. J. Mol. Sci.* 2019, 20, 4719. [CrossRef]

62. Karabon, L.; Markiewicz, M.; Kosmaczewska, A.; Partyka, A.; Pawlak-Adamska, E.; Ciszak, L.; Jagoda, K.; Dzierzak-Mietla, M.; Kyczor-Krzemien, S.; et al. Pretransplant donor and recipient CTLA-4 mRNA and protein levels as a prognostic marker for aGVHD in allogeneic hema-topoietic stem cell transplantation. *Immunol. Lett.* 2015, 165, 52–59. [CrossRef]

63. Rech, A.J.; Mick, R.; Martin, S.; Recio, A.; Aqui, N.A.; Powell, D.J.; Colligon, T.A.; Trosko, J.A.; Leinbach, L.I.; Pletcher, C.H.; et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. *Sci. Transl. Med.* 2012, 4, 134ra62. [CrossRef] [PubMed]

64. Marangoni, F.; Zhang, R.; Mani, V.; Thelen, M.; Ali Akbar, N.J.; Warner, R.D.; Ajijó, T.; Zappulli, V.; Martinez, G.J.; Turka, L.A.; et al. Tumor Tolerance-Promoting Function of Regulatory T Cells Is Optimized by CD28, but Strictly Dependent on Calcineurin. *J. Immunol.* 2018, 200, 3647–3661. [CrossRef] [PubMed]

65. De Groot, A.E.; Pienta, K.J. Epigenetic control of macrophage polarization: Implications for targeting tumor-associated macrophages. *OncoTarget* 2018, 9, 20908–20927. [CrossRef] [PubMed]

66. Prasmickaite, L.; Tenstad, E.M.; Pettersen, S.; Jabeen, S.; Egeland, E.V.; Nord, S.; Pandya, A.; Haugen, M.H.; Kristensen, V.N.; Børresen-Dale, A.L.; et al. Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4. *Mol. Oncol.* 2018, 12, 1540–1558. [CrossRef] [PubMed]

67. Alipoor, S.D.; Mortaz, E.; Varahram, M.; Movassaghi, M.; Kraneveld, A.D.; Garssen, J.; Adcock, I.M. The potential biomarkers and immunological effects of tumor-derived exosomes in lung cancer. *Front. Immunol.* 2018, 9, 819. [CrossRef] [PubMed]

68. Mantovani, A.; Sica, A.; Locati, M. New vistas on macrophage differentiation and activation. *Eur. J. Immunol.* 2007, 37, 14–16. [CrossRef] [PubMed]

69. Mantovani, A.; Sica, A.; Sozzani, S.; Allavena, P.; Vecchi, A.; Locati, M. The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol.* 2004, 25, 677–686. [CrossRef] [PubMed]

70. Tzeng, H.T.; Su, C.C.; Chang, C.P.; Lai, W.W.; Su, W.C.; Wang, Y.C. Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype. *Int. J. Cancer* 2018, 143, 1753–1763. [CrossRef] [PubMed]

71. Palaga, T.; Wongchana, W.; Kueanjinda, P. Notch Signaling in Macrophages in the Context of Cancer Immunity. *Front. Immunol.* 2018, 9, 652. [CrossRef] [PubMed]

72. Tan, Y.S.; Sansanaphongpricha, K.; Xie, Y.; Donnelly, C.R.; Luo, X.; Heath, B.R.; Zhao, X.; Bellile, E.; Hu, H.; Chen, H.; et al. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. *Clin. Cancer Res.* 2018, 24, 4242–4255. [CrossRef] [PubMed]

73. Savage, N.D.; de Boer, T.; Walburg, K.V.; Joosten, S.A.; van Meijgaard, K.; Geluk, A.; Ottenhoff, T.H. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta1. *J. Immunol.* 2008, 181, 2220–2226. [CrossRef] [PubMed]

74. Mantovani, A.; Marchesi, F.; Malesci, A.; Laghi, L.; Allavena, P. Tumour-associated macrophages as treatment targets in oncology. *Nat. Rev. Clin. Oncol.* 2017, 14, 399–416. [CrossRef] [PubMed]

75. Zhang, Q.W.; Liu, L.; Gong, C.Y.; Shi, H.S.; Zeng, Y.H.; Wang, X.Z.; Zhao, Y.W.; Wei, Y.Q. Prognostic significance of tumor-associated macrophages in solid tumor: A meta-analysis of the literature. *PLoS ONE* 2012, 7, e50946. [CrossRef] [PubMed]

76. Bates, R.C.; Pursell, B.M.; Mercurio, A.M. Epithelial-mesenchymal transition and colorectal cancer: Gaining insights into tumor progression using LIM 1863 cells. *Cells Tissues Organs* 2007, 185, 29–39. [CrossRef] [PubMed]

77. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. *Nat. Rev. Cancer* 2004, 4, 71–78. [CrossRef] [PubMed]
Aharinejad, S.; Abraham, D.; Paulus, P.; Abri, H.; Hofmann, M.; Grossschmidt, K.; Schäfer, R.; Stanley, E.R.; Hofbauer, R. Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. *Cancer Res.* 2002, 62, 5317–5324.

Bataille, F.; Rohrmeier, C.; Bates, R.; Weber, A.; Rieder, F.; Brennemoehl, J.; Strauch, U.; Forkas, S.; Fürst, A.; Hofstädter, F.; et al. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn’s disease. *Inflamm. Bowel Dis.* 2008, 14, 1514–1527. [CrossRef]

Guerrero, J.L. Macrophages: The road less traveled, changing anticancer therapy. *Trends Mol. Med.* 2018, 24, 472–489. [CrossRef]

Sinha, P.; Chormouguz, O.; Clements, V.K.; Artemenko, K.A.; Zubarev, R.A.; Ostrand-Rosenberg, S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. *Blood* 2011, 117, 5381–5390. [CrossRef] [PubMed]

Gabrilovich, D.I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat. Rev. Immunol.* 2009, 9, 162–174. [CrossRef] [PubMed]

Sieminska, I.; Baran, J. Myeloid-Derived Suppressor Cells in Colorectal Cancer. *Front. Immunol.* 2020, 11, 1526. [CrossRef] [PubMed]

Huang, B.; Pan, P.Y.; Li, Q.; Sato, A.I.; Levy, D.E.; Bromberg, J.; Divino, C.M.; Chen, S.H. Gr-1+CD115+ immature myeloid suppressor cells block immune surveillance against metastasis. *Cancer Res.* 2006, 66, 1123–1131. [CrossRef] [PubMed]

Sinha, P.; Clements, V.K.; Ostrand-Rosenberg, S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. *Cancer Res.* 2005, 65, 11743–11751. [CrossRef]

Gabrilovich, D.I.; Bronte, V.; Chen, S.H.; Colombo, M.P.; Ochoa, A.; Ostrand-Rosenberg, S.; Schreiber, H. The terminology issue for myeloid-derived suppressor cells. *Cancer Res.* 2007, 67, 425. [CrossRef]

Law, A.M.K.; Valdes-Mora, F.; Gallego-Ortega, D. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. *Cells* 2020, 9, 561. [CrossRef]

Gabrilovich, D.I.; Ostrand-Rosenberg, S.; Bronte, V. Coordinated regulation of myeloid cells by tumours. *Nat. Rev. Immunol.* 2012, 12, 253–268. [CrossRef]

Dumitru, C.A.; Moses, K.; Trellakis, S.; Lang, S.; Brandau, S. Neutrophils and granulocytic myeloid-derived suppressor cells: Immunophenotyping, cell biology and clinical relevance in human oncology. *Cancer Immunol. Immunother.* 2012, 61, 1155–1167. [CrossRef]

Kusmartsev, S.; Gabrilovich, D.I. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. *Cancer Metastasis Rev.* 2005, 24, 323–331. [CrossRef]

Meirow, Y.; Kanterman, J.; Baniyash, M. Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate. *Front. Immunol.* 2015, 6, 523. [CrossRef]

Martin, R.K.; Saleem, S.J.; Folgosa, L.; Zellner, H.B.; Damle, S.R.; Nguyen, G.K.; Ryan, J.J.; Bear, H.D.; Irani, A.M.; Conrad, D.H. Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. *J. Leukoc. Biol.* 2014, 96, 151–159. [CrossRef]

Salem, S.J.; Martin, R.K.; Morales, J.K.; Sturgill, J.L.; Gibb, D.R.; Graham, L.; Bear, H.D.; Manjili, M.H.; Ryan, J.J.; Conrad, D.H. Cutting edge: Mast cells critically augment myeloid-derived suppressor cell activity. *J. Immunol.* 2012, 189, 511–515. [CrossRef] [PubMed]

Burdan, F.; Chašlas, A.; Szumilo, J. Cyclooxygenase and prostanooid–znaczenie biologiczne [Cyclooxygenase and prostanooids–biological implications]. *Postepy Hig. Med. Dosw.* Online 2006, 60, 129–141.

Chun, E.; Lavoie, S.; Michaud, M.; Gallini, C.A.; Kim, J.; Soucy, G.; Odze, R.; Glickman, J.N.; Garrett, W.S. CCL2 Promotes Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. *Front. Immunol.* 2015, 6, 253. [CrossRef] [PubMed]

L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. *Cancer Res.* 2016, 76, 244–257. [CrossRef]

Rodriguez, P.C.; Zea, A.H.; Culotta, K.S.; Zabaleta, J.; Ochoa, J.B.; Ochoa, A.C. Regulation of T cell receptor CD3zeta chain expression by L-arginine. *J. Biol. Chem.* 2002, 277, 21123–21129. [CrossRef]

Rodriguez, P.C.; Quiceno, D.G.; Zabaleta, J.; Ortiz, B.; Zea, A.H.; Piazuelo, M.B.; Delgado, A.; Correa, P.; Brayer, J.; Sotomayor, E.M.; et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. *Cancer Res.* 2004, 64, 5839–5849. [CrossRef]

Rodriguez, P.C.; Quiceno, D.G.; Ochoa, A.C. L-arginine availability regulates T-lymphocyte cell-cycle progression. *Blood* 2007, 109, 1568–1573. [CrossRef]

Obermaier, N.; Muthuswamy, R.; Lesnock, J.; Edwards, R.P.; Kalinski, P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-suppressor cells. *Blood* 2011, 118, 5498–5505. [CrossRef]

Han, C.; Demetris, A.J.; Stolz, D.B.; Xu, L.; Lim, K.; Wu, T. Modulation of Stat3 Activation by the cytosolic phospholipase a 2 α and cyclooxygenase2-controlled prostaglandin E2 signaling pathway. *J. Biol. Chem.* 2006, 281, 24831–24846. [CrossRef]

Corvinu, F.M.; Orth, C.; Moriggl, R.; Tsareva, S.A.; Wagner, S.; Pfützner, E.B.; Baus, D.; Kaufmann, R.; Huber, L.A.; Zatloukal, K.; et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. *Neoplasia* 2005, 7, 545–555. [CrossRef]
103. Lee, H.; Herrmann, A.; Deng, J.H.; Kujawski, M.; Niu, G.; Li, Z.; Forman, S.; Jove, R.; Pardoll, D.M.; Yu, H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15, 283–293. [CrossRef] [PubMed]

104. Ma, P.; Beatty, P.L.; McKolanis, J.; Brand, R.; Schoen, R.E.; Finn, O.J. Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignant share phenotypic and functional characteristics with MDSC in cancer. Front. Immunol. 2019, 10, 1401. [CrossRef] [PubMed]

105. Yang, L.; DeBusk, L.M.; Fukuda, K.; Fingleton, B.; Green-Jarvis, B.; Shyr, Y.; Matrisian, L.M.; Carbone, D.P.; Lin, P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6, 409–421. [CrossRef] [PubMed]

106. Mira, E.; Lalcake, R.A.; Buesa, J.M.; de Buitrago, G.G.; Jiménez-Baranda, S.; Gómez-Moutón, C.; Martínez-A, C.; Mañes, S. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J. Cell Sci. 2004, 117, 1847–1857. [CrossRef]

107. Yang, L.; Huang, J.; Ren, X.; Gorska, A.E.; Chytil, A.; Aakre, M.; Carbone, D.P.; Matrisian, L.M.; Richmond, A.; Lin, P.C.; et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13, 23–35. [CrossRef] [PubMed]

108. Toh, B.; Wang, X.; Keeble, J.; Sim, W.J.; Khoo, K.; Wong, W.C.; Kato, M.; Prevost-Blondel, A.; Thiery, J.P.; Abastado, J.P. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011, 9, e1001162. [CrossRef]

109. Suzuki, E.; Kapoor, V.; Jazzar, A.S.; Kaiser, L.R.; Albelda, S.M. Gemcitabine selectively eliminates splenic Gr+CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11, 6713–6721. [CrossRef]

110. Sevko, A.; Michels, T.; Vrohlings, M.; Umansky, L.; Beckhove, P.; Kato, M.; Shurin, G.V.; Shurin, M.R.; Umansky, V. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 2013, 190, 2464–2471. [CrossRef]

111. Eriksson, E.; Wenthe, J.; Irenaeus, S.; Loskog, A.; Ullenhag, G. Gemcitabine reduces MDSCs, tregs and TGF-beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J. Transl. Med. 2016, 14, 282. [CrossRef]

112. Vincent, J.; Mignot, G.; Chalmin, F.; Ladoire, S.; Bruchard, M.; Chevriaux, A.; Martin, F.; Apetoh, L.; Rhee, H.; et al. Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15, 283–293. [CrossRef] [PubMed]

113. Ko, J.S.; Zea, A.H.; Rini, B.I.; Ireland, J.L.; Elson, P.; Cohen, P.; Golshayan, A.; Rayman, P.A.; Wood, L.; Garcia, J.; et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009, 15, 2148–2157. [CrossRef]

114. Kodera, Y.; Katanasaka, Y.; Kitamura, Y.; Tsuda, H.; Nishio, K.; Tamura, T.; Koizumi, F. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res. 2011, 13, R66. [CrossRef]

115. Weber, R.; Fleming, V.; Hu, X.; Nagibin, V.; Groth, C.; Altevogt, P.; Uitkal, J.; Umansky, V. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Front. Immunol. 2018, 9, 1310. [CrossRef]

116. Katoh, H.; Wang, D.; Daikoku, T.; Sun, H.; Dey, S.K.; Dubois, R.N. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorogenesis. Cancer Cell 2016, 29, 631–644. [CrossRef]

117. Steele, C.W.; Karim, S.A.; Leach, J.D.G.; Bailey, P.; Upstill-Goddard, R.; Rishi, L.; Foth, M.; Bryson, L.; Wood, L.; Garcia, J.; et al. Sunitinib reveals reversal of myeloid-derived suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Cancer Cell 2016, 29, 832–845. [CrossRef]

118. Veltman, J.D.; Lambers, M.E.; van Nimwegen, M.; Hendriks, R.W.; Hoogsteden, H.C.; Aerts, J.G.; Hegmans, J.P. COX-2 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Cancer Res. 2017, 77, 3052–3061. [CrossRef]

119. Serafini, P.; Meckel, K.; Kelso, M.; Noonan, K.; Califano, J.; Koch, W.; Dolcetti, L.; Bronte, V.; Borrello, I. Phosphodiesterase-5 inhibitors immunotherapeutic properties. Cancer Cell 2009, 15, 2148–2157. [CrossRef] [PubMed]

120. Serafini, P.; Meckel, K.; Kelso, M.; Noonan, K.; Califano, J.; Koch, W.; Dolcetti, L.; Bronte, V.; Borrello, I. Phosphodiesterase-5 inhibitors immunotherapeutic properties. Cancer Cell 2009, 15, 2148–2157. [CrossRef] [PubMed]

121. Orillion, A.; Hashimoto, A.; Damayanti, N.; Shen, L.; Adelayi-Ogala, R.; Arisa, S.; Chintala, S.; Ordentlich, P.; Kao, C.; Elzey, B.; et al. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin. Cancer Res. 2017, 23, 5187–5201. [CrossRef] [PubMed]

122. Kim, K.; Skora, A.D.; Li, Z.; Liu, Q.; Tam, A.J.; Blosser, R.L.; Diaz, L.A., Jr.; Papadopoulos, N.; Kinzler, K.W.; Vogelstein, B.; et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. USA 2014, 111, 1174–1179. [CrossRef] [PubMed]

123. De la Torre, P.; Pérez-Lorenzo, M.J.; Alcázar-Garrido, A.; Flores, A.I. Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments. Molecules 2020, 25, 715. [CrossRef] [PubMed]

124. Shao, K.; Singha, S.; Clemente-Casares, X.; Tsai, S.; Yang, Y.; Santamaria, P. Nanoparticle-based immunotherapy for cancer. ACS Nano 2015, 9, 16–30. [CrossRef]
125. Fan, Y.; Moon, J.J. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. *Vaccines* 2015, 3, 662–685. [CrossRef]

126. He, C.; Duan, X.; Guo, N.; Chan, C.; Poon, C.; Weichselbaum, R.R.; Lin, W. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. *Nat. Commun.* 2016, 7, 12499–12511. [CrossRef]

127. Mortezaee, K.; Khanlarkhani, N. Melatonin application in targeting oxidative-induced liver injuries: A review. *J. Cell. Physiol.* 2018, 233, 4015–4032. [CrossRef]

128. Song, W.; Shen, L.; Wang, Y.; Liu, Q.; Goodwin, T.J.; Li, J.; Dorosheva, O.; Liu, T.; Liu, R.; Huang, L. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. *Nat. Commun.* 2018, 9, 2237–2248. [CrossRef]

129. Verma, R.P.; Hansch, C. Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs. *Bioorg. Med. Chem.* 2007, 15, 2223–2268. [CrossRef]

130. Serra, R.; Gallelli, L.; Grande, R.; Amato, B.; De Caridi, G.; Sammarco, G.; Ferrari, F.; Butrico, L.; Gallo, G.; Rizzuto, A.; et al. Hemorrhoids and matrix metalloproteinases: A multicenter study on the predictive role of biomarkers. *Surgery* 2016, 159, 487–494. [CrossRef]

131. Lucafò, M.; Pugnetti, L.; Bramuzzo, M.; Curci, D.; Di Silvestre, A.; Marcuzzi, A.; Bergamo, A.; Martelossi, S.; Villanacci, V.; Bozzola, A.; et al. Long Non-Coding RNA GAS5 and Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients with IBD. *Int. J. Mol. Sci.* 2019, 20, 5280. [CrossRef]

132. Herszényi, L.; Hritz, I.; Lakatos, G.; Varga, M.Z.; Tulassay, Z. The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. *Int. J. Mol. Sci.* 2012, 13, 13240–13263. [CrossRef]

133. Hilska, M.; Roberts, P.J.; Collan, Y.U.; Laine, V.J.O.; Kössi, J.; Hirsimäki, P.; Rahkonen, O.; Laato, M. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. *Int. J. Cancer* 2007, 121, 714–723. [CrossRef] [PubMed]

134. Ribatti, D.; Vacca, A.; Nico, B.; Crivellato, E.; Roncali, L.; Dammacco, F. The role of mast cells in tumour angiogenesis. *Br. J. Haematol.* 2001, 115, 514–521. [CrossRef] [PubMed]

135. Gulubova, M.; Vlaykova, T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. *J. Gastroenterol. Hepatol.* 2009, 24, 1265–1275. [CrossRef]

136. Raeeszadeh-Sarmazdeh, M.; Do, L.D.; Hritz, B.G. Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics. *Cells* 2020, 9, 1313. [CrossRef]

137. Ribatti, D. Mast cells as therapeutic target in cancer. *Eur. J. Pharmacol.* 2016, 778, 152–157. [CrossRef]